Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Villaruz on EGFR-Targeted Therapies in NSCLC

October 18th 2018

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses EGFR-targeted therapies in non–small cell lung cancer.

Dr. Leighl Discusses Binimetinib in KRAS-Mutated NSCLC

October 17th 2018

Natasha Leighl, MD, medical oncologist, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, discusses binimetinib (Mektovi) in KRAS-mutated non–small cell lung cancer.

Dr. Kerr on Misconceptions With Molecular Profiling in Lung Cancer

October 16th 2018

Keith Kerr, BSc, MB, ChB, consultant pathologist, University of Aberdeen, Aberdeen, Scotland, discusses common misconceptions with molecular profiling in lung cancer.

Dr. Horn Discusses Next Steps With Atezolizumab in SCLC

October 16th 2018

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses next steps with atezolizumab (Tecentriq) in small cell lung cancer.

FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer

October 15th 2018

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options.

Take-Home Messages on the NSCLC Treatment Paradigm

October 15th 2018

Other Targeted Approaches in NSCLC: NTRK or RET Fusions

October 15th 2018

Considering Targeted Agents in BRAF-Mutant NSCLC

October 15th 2018

Sequencing Therapies in ALK-Rearranged NSCLC

October 15th 2018

Changing the Treatment Paradigm for ALK-Rearranged NSCLC

October 15th 2018

Global Perspectives on Use of Osimertinib in EGFR+ NSCLC

October 15th 2018

Osimertinib's Role in EGFR+ Metastatic Lung Cancer

October 15th 2018

Managing Oligometastases With Ablative Therapy in NSCLC

October 15th 2018

CheckMate 227: TMB Versus PD-L1 in Advanced-Stage NSCLC

October 15th 2018

Treatment After Progression in Advanced-Stage NSCLC

October 15th 2018

Personal Use of I-O Therapy in Advanced-Stage NSCLC

October 15th 2018

Advanced-Stage NSCLC: KEYNOTE-189's Role in Treatment

October 15th 2018

Appropriate Settings for the PACIFIC Regimen in NSCLC

October 15th 2018

Global Perspectives on the PACIFIC Trial in NSCLC

October 15th 2018

Locally Advanced NSCLC: Approaching the PACIFIC Trial

October 15th 2018